These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 2482776)

  • 1. Pathogenesis and medical treatment of benign prostatic hyperplasia.
    Geller J
    Prostate Suppl; 1989; 2():95-104. PubMed ID: 2482776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonsurgical treatment of prostatic hyperplasia.
    Geller J
    Cancer; 1992 Jul; 70(1 Suppl):339-45. PubMed ID: 1376202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of benign prostatic hypertrophy.
    Geller J
    Urology; 1989 Oct; 34(4 Suppl):57-63; discussion 87-96. PubMed ID: 2477935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benign prostatic hyperplasia: pathogenesis and medical therapy.
    Geller J
    J Am Geriatr Soc; 1991 Dec; 39(12):1208-16. PubMed ID: 1720438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content.
    Forti G; Salerno R; Moneti G; Zoppi S; Fiorelli G; Marinoni T; Natali A; Costantini A; Serio M; Martini L
    J Clin Endocrinol Metab; 1989 Feb; 68(2):461-8. PubMed ID: 2465302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of castration compared with total androgen blockade on tissue dihydrotestosterone (DHT) concentration in benign prostatic hyperplasia (BPH).
    Geller J; Albert J
    Urol Res; 1987; 15(3):151-3. PubMed ID: 3629749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benign prostatic hyperplasia. Practical treatment guidelines.
    Tammela T
    Drugs Aging; 1997 May; 10(5):349-66. PubMed ID: 9143856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing approaches in the treatment of benign prostatic hyperplasia.
    Schröder FH
    Eur Urol; 1991; 20 Suppl 1():63-7. PubMed ID: 1722165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical treatment of benign prostatic hyperplasia: 5 alpha-reductase inhibitors and alpha-adrenergic antagonists.
    Monda JM; Oesterling JE
    Mayo Clin Proc; 1993 Jul; 68(7):670-9. PubMed ID: 7688840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New conservative therapeutic approaches in benign prostatic hyperplasia].
    Schulze H; Berges R; Paschold K; Senge T
    Urologe A; 1992 Jan; 31(1):8-13. PubMed ID: 1372777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical management of prostatic diseases.
    Schlegel PN
    Adv Intern Med; 1994; 39():569-601. PubMed ID: 7511322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen and androgen signaling in the pathogenesis of BPH.
    Ho CK; Habib FK
    Nat Rev Urol; 2011 Jan; 8(1):29-41. PubMed ID: 21228820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk.
    Emberton M; Zinner N; Michel MC; Gittelman M; Chung MK; Madersbacher S
    BJU Int; 2007 Aug; 100(2):249-53. PubMed ID: 17617135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benign prostatic hyperplasia: drug and nondrug therapies.
    Bruskewitz RC
    Geriatrics; 1992 Dec; 47(12):39-42, 45. PubMed ID: 1280242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of sex steroids in the pathogenesis and maintenance of benign prostatic hyperplasia.
    Levine AC; Kirschenbaum A; Gabrilove JL
    Mt Sinai J Med; 1997 Jan; 64(1):20-5. PubMed ID: 8997072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basis for hormonal management of advanced prostate cancer.
    Geller J
    Cancer; 1993 Feb; 71(3 Suppl):1039-45. PubMed ID: 7679038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
    Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
    J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Application of antiandrogens on prostatic diseases].
    Takahashi S; Hasegawa F; Isurugi K
    Nihon Rinsho; 1994 Mar; 52(3):809-14. PubMed ID: 7513031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormonal and morphologic evaluation of the effects of antiandrogens on the blood supply of the rat prostate.
    Shibata Y; Ono Y; Kashiwagi B; Suzuki K; Fukabori Y; Honma S; Yamanaka H
    Urology; 2003 Nov; 62(5):942-6. PubMed ID: 14624931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
    Habib FK; Ross M; Tate R; Chisholm GD
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.